Galectin-3, a prognostic marker--and a therapeutic target?

Area of Science:

• Cardiology
• Biomarker Discovery
• Molecular Biology

Background:

• Natriuretic peptides (BNP, NT-proBNP) are standard heart failure biomarkers but have limitations.
• Galectin-3, a protein implicated in cardiac fibrosis and remodeling, is elevated in fibrotic hearts.
• Elevated galectin-3 is associated with worse prognosis and increased rehospitalization/mortality in heart failure.

Purpose of the Study:

• To evaluate galectin-3 as a novel biomarker for heart failure.
• To assess the combined prognostic value of galectin-3 with natriuretic peptides.
• To explore galectin-3's potential in improving heart failure screening, diagnosis, and prognosis.

Main Methods:

• The study focuses on the role and expression of galectin-3 in cardiac tissue.
• Analysis of galectin-3 levels (>17.8 ng/ml) in chronic heart failure patients.
• Comparative assessment of galectin-3 and natriuretic peptides for prognostic value.

Main Results:

• Galectin-3 expression is low in normal hearts but increases with cardiac fibrosis.
• Elevated galectin-3 is present in 30-50% of chronic heart failure patients.
• Galectin-3 demonstrates significant prognostic value, exceeding that of natriuretic peptides alone.
• Combining galectin-3 with BNP or NT-proBNP further enhances prognostic accuracy.

Conclusions:

• Galectin-3 is a valuable biomarker for identifying patients with worse heart failure prognosis.
• Combination therapy with galectin-3 and natriuretic peptides may improve heart failure management.
• Targeting galectin-3 pathways could offer therapeutic strategies for heart failure progression.